

CenterWell Specialty Pharmacy™

Monday – Friday: 8 a.m. – 11 p.m. ET
Saturday: 8 a.m. – 6:30 p.m. ET

Remove above portion before faxing. Please complete the prescription form in its entirety and fax to the number above.

Lysosomal Storage Disorders Form

Patient Information

Patient: _____ ☐ Female ☐ Male DOB: _____ Insurance Plan: _____ Plan ID #: _____
Address: _____ City: _____ State: _____ Zip Code: _____
Home Phone #: _____ Cell Phone #: _____ Caregiver: _____ Caregiver Phone #: _____
Other Medical Conditions: _____ Allergies: ☐ No ☐ Yes: _____

Clinical information: Please Include History and Physical (H&P) and latest visit note including infection history/treatment for past 6 months

ICD-10 code: ☐ Fabry Disease E7521 ☐ Gaucher Disease E7522 ☐ Hunter Syndrome E76.1 ☐ Hurler's Syndrome E76.01
☐ Lysosomal Alpha 1 Deficiency E74.02 ☐ Mucopolysaccharidosis VI (MPS-VI) E76.29 ☐ Pompe Disease E74.02
☐ Sanfilippo syndrome (Mucopolysaccharidosis III) E76.3 ☐ Scheie's Syndrome E76.03 ☐ Other: _____
Diagnosis date: _____ Height: _____ Weight: _____ ☐ lb ☐ kg Date: _____

Additional PA ☐ New therapy ☐ Continuing therapy ☐ Investigational First dose? ☐ Yes ☐ No Expected date of first/next infusion: _____

Venous access: ☐ Peripheral ☐ Port ☐ PICC ☐ CL: Type _____ Infuse via ☐ PUMP ☐ Gravity as tolerated by patient ☐ Other: _____

☐ Skilled nursing visit to establish venous access, patient education related to therapy & disease state, administer medication as prescribed, assess general status, and response to therapy. Visit frequency based on prescribed dosage orders.

Prescription Information NOTE: OH law allows 1 prescription per preprinted order form. Please use additional forms for more than 1 prescription.

| Medication | Dose | Directions | Quantity | Refills |
|--|---|--|---|---|
| <input type="checkbox"/> Aldurazyme® | <input type="checkbox"/> 2.9 mg vial | Dose: _____ mg units IV Volume to infuse: _____ Frequency: _____ Rate (ml): _____ <input type="checkbox"/> Titrate per manufacturer guidelines | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Cerezyme® | <input type="checkbox"/> 400 unit vial | | | |
| <input type="checkbox"/> Elaprase® | <input type="checkbox"/> 6 mg vial | | | |
| <input type="checkbox"/> Fabrazyme® | <input type="checkbox"/> 5 mg vial <input type="checkbox"/> 35 mg vial | | | |
| <input type="checkbox"/> Lumizyme® | <input type="checkbox"/> 50 mg vial | | | |
| <input type="checkbox"/> VPRIV® | <input type="checkbox"/> 200 unit vial <input type="checkbox"/> 400 unit vial | | | |
| <input type="checkbox"/> Nexvazyme | <input type="checkbox"/> 100 mg vial | | | |
| <input type="checkbox"/> Cerdelga | <input type="checkbox"/> 84mg Capsule | Take 1 capsule _____ times (s) per day. | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Miglustat | <input type="checkbox"/> 100mg Capsule | Take 1 capsule _____ times (s) per day. | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Sterile Water | <input type="checkbox"/> 10 ml | UAD for reconstitution of Enzyme | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Sodium Chloride 0.9% | <input type="checkbox"/> 100ml <input type="checkbox"/> 200ml <input type="checkbox"/> 500ml | Use to further dilute reconstituted Enzyme | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Normal saline flush | <input type="checkbox"/> 10 ml PFS | Flush line with 5-10 mls before & after IV drug & PRN line care | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Heparin 100 units flush | <input type="checkbox"/> 5 ml PFS | Flush line with 3-5 mls post infusion & PRN line care | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Lidocaine/Prilocaine Cream 2.5%-2.5% | <input type="checkbox"/> 30gm | Apply topically to needle insertion site 30-60 minutes prior to needle insertion as directed | <input type="checkbox"/> 28 Day Supply | <input type="checkbox"/> _____ |
| Pretreatment: <input type="checkbox"/> acetaminophen <input type="checkbox"/> 325 mg tablet <input type="checkbox"/> 500 mg tablet <input type="checkbox"/> diphenhydramine <input type="checkbox"/> 25 mg capsule <input type="checkbox"/> 50 mg tablet | | <input type="checkbox"/> Take _____ mg p.o. 30–60 min. prior to inf. and q4–6 p.r.n. Max. four doses in 24 hr. <input type="checkbox"/> _____ | <input type="checkbox"/> 10 capsules <input type="checkbox"/> 10 tablets <input type="checkbox"/> _____ | <input type="checkbox"/> 11 <input type="checkbox"/> _____ |
| Anaphylaxis Kit (Patient's home): | <input type="checkbox"/> Epinephrine 0.3 mg auto-injector | <input type="checkbox"/> Inject IM p.r.n. anaphylaxis | <input type="checkbox"/> 2-pack | <input type="checkbox"/> 0 <input type="checkbox"/> _____ |
| | <input type="checkbox"/> Epinephrine 0.15 mg auto-injector (patients 15–30 kg) | <input type="checkbox"/> Inject IM p.r.n. anaphylaxis | <input type="checkbox"/> 2-pack | |
| | <input type="checkbox"/> Diphenhydramine 25 mg capsules | <input type="checkbox"/> Take 25–50 mg PO p.r.n. anaphylaxis | <input type="checkbox"/> 10 capsules | |
| | <input type="checkbox"/> Diphenhydramine 50 mg/mL injection | <input type="checkbox"/> Inject slow IV push p.r.n anaphylaxis | <input type="checkbox"/> 1 vial | |

Pharmacy to dispense ancillary supplies as needed to establish IV and administer drug.

Prescriber and Shipping Information (Please print)

Prescriber: _____ NPI: _____
Ship to: ☐ Patient ☐ Office ☐ Other: _____
Office Address: _____ City: _____ State: _____ Zip Code: _____
Office Phone Number: _____ Office Fax Number: _____
Signature: _____ Date: _____

We will dispense this prescription as generic, unless the prescriber indicates "Dispense as Written" _____
The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.